Overview of Dr. Konner
Dr. Jason Konner is an oncologist in Middletown, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Hackensack Meridian Health Riverview Medical Center, Memorial Sloan Kettering Monmouth, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Stanford University School of Medicine and has been in practice 18 years. Dr. Konner accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 45 doctors at Hackensack Meridian Health Riverview Medical Center who specialize in Oncology. He has more than 90 publications and over 500 citings.
Office
480 Red Hill Road
Middletown, NJ 07748Fax+1 646-888-4265
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1999 - 2001
- Stanford University School of MedicineClass of 1999
- Yale CollegeBS, 1990 - 1994
Certifications & Licensure
- FL State Medical License 2023 - Present
- NJ State Medical License 2016 - 2025
- NY State Medical License 2000 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer Start of enrollment: 2005 Jun 01
- Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Start of enrollment: 2006 Aug 01
- Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.Sujana Movva, Kenneth Seier, Viswatej Avutu, Lauren B Banks, Jason Chan
Clinical Cancer Research. 2024-12-16 - A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Angela K Green, Qin Zhou, Alexia Iasonos, William A Zammarrelli, Britta Weigelt
Clinical Cancer Research. 2024-11-19 - Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.Aditi Gupta, Roisin E O'Cearbhaill, Matthew S Block, Erika Hamilton, Jason A Konner
Gynecologic Oncology. 2024-10-01
Journal Articles
- A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian CancerKaren A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology
Press Mentions
- 5 Warning Signs of Ovarian Cancer Every Woman Should KnowJune 23rd, 2022
- I Promised My Sister I Would Write About How She Chose to DieJanuary 4th, 2024
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
Empire BCBS HMO
Empire BCBS PPOFirst Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: